GET DAILY SIGNALSWhy Is Axon Enterprise (AXON) Stock Down -16.88% Today?
Key Takeaways
- Shares fell about 16.88% intraday, dropping from a prior close of $382.56 to roughly $317.97.
- Primary catalyst: A third-quarter earnings miss and a cut to full-year revenue guidance tied to delayed federal Dedrone (counter-drone) deployments.
- Secondary drivers: A wave of analyst price-target cuts and downgrades, plus a capital-intensive $1.2 billion investment in drone maker Skydio.
- Broader context: The decline was company-specific — the Nasdaq and S&P 500 both traded higher on the day.
- What to watch: Whether the roughly $130 million in deferred federal revenue shifts into 2027 or reflects a deeper slowdown in government purchasing.
- Explore detailed Price Targets, Earnings, and Forecast data for deeper insight into this stock.
- Discover how automated strategies are navigating this volatility by exploring Trending AI Robots.
Opening Summary
Axon Enterprise, Inc. (AXON) — the maker of TASER conducted-energy devices, body-worn cameras, and cloud-based software for law enforcement and public safety — saw its shares plunge roughly 16.88% in Friday's session, trading near $317.97 after closing the prior session at $382.56. The selloff extended a sharp after-hours decline that began when the company reported third-quarter results late Thursday. Markets pointed to an earnings and revenue miss, a lowered full-year outlook driven by slower federal drone deployments, and a sizable new capital commitment as the primary reasons for the steep drop.
Earnings Miss and Guidance Cut
The stock's slide was driven first by a downbeat third-quarter report. AXON posted record revenue of $908.55 million, up about 28% year over year, but that figure fell short of Wall Street's consensus of roughly $934 million to $940 million. Adjusted earnings of $1.72 per share also missed estimates near $1.88 to $1.91, even as adjusted EBITDA rose 33% to about $236 million.
More damaging was the outlook. Management trimmed full-year 2026 revenue guidance to a range of $3.61 billion to $3.63 billion, down from a prior range of $3.67 billion to $3.725 billion, citing three federal Dedrone deployments worth about $130 million that are no longer expected to be recognized this year. Fourth-quarter revenue guidance of $990 million to $1.01 billion also came in below the roughly $1.06 billion analysts had modeled. The company separately lowered its free-cash-flow target to $350 million to $400 million from about $450 million, reflecting an accelerated inventory build.
Federal Drone Delays and the Skydio Bet
The guidance cut stemmed largely from lumpy, big-ticket government purchasing cycles. Management attributed the shortfall to roughly $30 million of Dedrone revenue that slipped out of the third quarter and about $100 million more expected in the fourth quarter. That concentrated federal-timing risk rattled investors who had priced AXON for consistent hypergrowth.
At the same time, the company announced an additional $1.2 billion investment in Skydio, raising its stake in the drone maker to 37% and securing exclusive public-safety distribution rights in the U.S. and Canada. While framed as a strategic bet on "Drone as First Responder" technology, the capital-intensive commitment added near-term pressure as investors weighed dilution and execution risk against the long-term opportunity.
Analyst Reaction
Sell-side responses amplified the decline. Needham cut its price target to $500 from $750, Piper Sandler trimmed its target to $540 from $561, and Baird lowered its target to $600 from $675. Zacks downgraded the stock from "strong buy" to "hold." The cluster of downward revisions underscored Wall Street's concern that the company's premium valuation offered little cushion for a guidance step-down.
Market Context and Trading Activity
The drop was clearly idiosyncratic rather than macroeconomic. The Nasdaq Composite gained about 1.7% and the S&P 500 advanced modestly on the day, confirming that AXON was moving against the broader tape. Volume surged well above average as investors repriced the shares, which traded near and below their prior 52-week low and well beneath their 50-day and 200-day moving averages. The move pushed the stock to new one-year lows, breaking through previously established support levels.
What Comes Next for AXON
Investors will focus on whether the roughly $130 million in deferred federal Dedrone revenue simply shifts into 2027 or signals a more persistent slowdown in government procurement. The company's software story remains a bright spot — Software & Services revenue grew 43% to $437 million, annual recurring revenue rose 40% to $1.75 billion, and AI annual recurring revenue crossed $100 million — but the market now appears more skeptical of the consolidated growth rate. Upcoming earnings reports, any clarity on federal contract timing, and the execution of the Skydio partnership will be closely watched. Risks include continued lumpiness in federal orders, margin pressure from hardware mix and memory costs, and the possibility of further multiple compression if growth decelerates again.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of the platform's strongest-performing AI trading bots under current market conditions. Tickeron offers hundreds of automated bots covering thousands of tickers, with each bot varying by strategy, timeframe, performance metrics, and traded symbols. Only the top performers are featured in this section, helping traders identify approaches that are adapting to today's volatility. Explore the page to see which strategies are currently standing out.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
AXON in upward trend: price may jump up because it broke its lower Bollinger Band on October 16, 2026
AXON may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 28 of 33 cases where AXON's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where AXON's RSI Indicator exited the oversold zone, 19 of 27 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 70%.
The Moving Average Convergence Divergence (MACD) for AXON just turned positive on October 06, 2026. Looking at past instances where AXON's MACD turned positive, the stock continued to rise in 28 of 37 cases over the following month. The odds of a continued upward trend are 76%.
Following a +1.31% 3-day Advance, the price is estimated to grow further. Considering data from situations where AXON advanced for three days, in 273 of 370 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 42 of 57 cases where AXON's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 74%.
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AXON as a result. In 56 of 76 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 74%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AXON declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 70%.
The Aroon Indicator for AXON entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating steady price growth. AXON’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 69 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AXON’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 79, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 76 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 81 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 93 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.458) is normal, around the industry mean (4.689). AXON has a moderately high P/E Ratio (154.883) as compared to the industry average of (17.589). Projected Growth (PEG Ratio) (1.949) is also within normal values, averaging (3.110). Dividend Yield (0.000) settles around the average of (0.058) among similar stocks. P/S Ratio (12.034) is also within normal values, averaging (18.367).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a clinical-stage biopharmaceutical company
Industry AerospaceDefense
Advertisement